A BILL 
To direct the Secretary of Veterans Affairs to carry out 
a clinical trial of the effects of cannabis on certain health 
outcomes of adults with chronic pain and post-traumatic 
stress disorder, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘VA Medicinal Cannabis 
4
Research Act of 2019’’. 
5
02:59 Feb 01, 2019
H712
2 
•HR 712 IH
SEC. 2. DEPARTMENT OF VETERANS AFFAIRS CLINICAL 
1
TRIAL OF THE EFFECTS OF CANNABIS ON 
2
CERTAIN HEALTH OUTCOMES OF ADULTS 
3
WITH CHRONIC PAIN AND POST-TRAUMATIC 
4
STRESS DISORDER. 
5
(a) CLINICAL TRIAL REQUIRED.— 
6
(1) IN GENERAL.—The Secretary of Veterans 
7
Affairs shall carry out a double-blind randomized 
8
controlled clinical trial of the effects of medical- 
9
grade cannabis on the health outcomes of covered 
10
veterans diagnosed with chronic pain and covered 
11
veterans diagnosed with post-traumatic stress dis-
12
order. 
13
(2) REQUIRED ELEMENTS.—The clinical trial 
14
required by paragraph (1) shall include— 
15
(A) with respect to covered veterans diag-
16
nosed with chronic pain, an evaluation of the 
17
effects of the use of cannabis on— 
18
(i) neuropathic pain (including pain 
19
intensity and pain-related outcomes); 
20
(ii) the reduction or increase in opioid 
21
use or dosage; 
22
(iii) the reduction or increase in 
23
benzodiazepine use or dosage; 
24
(iv) the reduction or increase in alco-
25
hol use; 
26
02:59 Feb 01, 2019
H712
3 
•HR 712 IH
(v) inflammation; 
1
(vi) sleep quality; 
2
(vii) spasticity; 
3
(viii) agitation; and 
4
(ix) quality of life; and 
5
(B) with respect to covered veterans diag-
6
nosed with post-traumatic stress disorder 
7
(PTSD), an evaluation of the effects of the use 
8
of cannabis on— 
9
(i) the symptoms of PTSD (based on 
10
the Clinician Administered PTSD Scale, 
11
the PTSD checklist, the PTSD symptom 
12
scale, the posttraumatic diagnostic scale, 
13
and other applicable methods of evaluating 
14
PTSD symptoms); 
15
(ii) the reduction or increase in 
16
benzodiazepine use or dosage; 
17
(iii) the reduction or increase in alco-
18
hol use; 
19
(iv) mood; 
20
(v) anxiety; 
21
(vi) social functioning; 
22
(vii) agitation; 
23
(viii) suicidal ideation; and 
24
02:59 Feb 01, 2019
H712
4 
•HR 712 IH
(ix) sleep quality, including frequency 
1
of nightmares and night terrors. 
2
(3) OPTIONAL
ELEMENTS.—The clinical trial 
3
required by paragraph (1) may include an evaluation 
4
of the effects of the use of cannabis to treat chronic 
5
pain and PTSD on— 
6
(A) pulmonary function; 
7
(B) cardiovascular events; 
8
(C) head, neck, and oral cancer; 
9
(D) testicular cancer; 
10
(E) ovarian cancer; 
11
(F) transitional cell cancer; 
12
(G) motor vehicle accidents; 
13
(H) mania; 
14
(I) psychosis; 
15
(J) cognitive effects; or 
16
(K) cannabinoid hyperemesis syndrome. 
17
(b) COVERED VETERANS.—In this section, the term 
18
‘‘covered veteran’’ means a veteran who is enrolled in the 
19
patient enrollment system of the Department of Veterans 
20
Affairs under section 1705 of title 38, United States Code. 
21
(c) LONG-TERM OBSERVATIONAL STUDY.—The Sec-
22
retary may carry out a long-term observational study of 
23
the participants in the clinical trial required under sub-
24
section (a). 
25
02:59 Feb 01, 2019
H712
5 
•HR 712 IH
(d) TYPE OF CANNABIS.—In carrying out the clinical 
1
trial required by subsection (a), the Secretary shall 
2
study— 
3
(1) varying forms of cannabis, including— 
4
(A) full plants and extracts; and 
5
(B) at least three different strains of can-
6
nabis with significant variants in phenotypic 
7
traits 
and 
various 
ratios 
of 
8
tetrahydrocannabinol and cannabidiol in chem-
9
ical composition; and 
10
(2) varying methods of cannabis delivery, in-
11
cluding combustible and non-combustible inhalation 
12
and ingestion. 
13
(e) 
USE
OF
CONTROL
AND
EXPERIMENTAL 
14
GROUPS.—The clinical trial required by subsection (a) 
15
shall include both a control group and an experimental 
16
group which shall— 
17
(1) be of similar size and structure; and 
18
(2) represent the demographics of the veteran 
19
population, as determined by the most recent data 
20
from the American Community Survey that is avail-
21
able prior to the commencement of the clinical trial. 
22
(f) DATA PRESERVATION.—The clinical trial required 
23
by subsection (a) shall include a mechanism to ensure the 
24
preservation of all data, including all data sets, collected 
25
02:59 Feb 01, 2019
H712
6 
•HR 712 IH
or used for purposes of the research required by sub-
1
section (a) in a manner that will facilitate further re-
2
search. 
3
(g) IMPLEMENTATION.—Not later than 180 days 
4
after the date of the enactment of this Act, the Secretary 
5
shall— 
6
(1) develop a plan to implement this section 
7
and submit such plan to the Committees on Vet-
8
erans’ Affairs of the House of Representatives and 
9
the Senate; and 
10
(2) issue any requests for proposals the Sec-
11
retary determines appropriate for such implementa-
12
tion. 
13
(h) EFFECT ON OTHER BENEFITS.—The eligibility 
14
or entitlement of a covered veteran to any other benefit 
15
under the laws administered by the Secretary or any other 
16
provision of law shall not be affected by the participation 
17
of the covered veteran in a clinical trial or study under 
18
this section. 
19
(i) REPORTS.—During the five-year period beginning 
20
on the date of the enactment of this Act, the Secretary 
21
shall submit periodically, but not less frequently than an-
22
nually, to the Committees on Veterans’ Affairs of the 
23
02:59 Feb 01, 2019
H712
7 
•HR 712 IH
House of Representatives and the Senate reports on the 
1
implementation of this section. 
2
Æ 
02:59 Feb 01, 2019
H712
